Skip to content

Coverage regarding Targovax’s presentation at ESGCT/ISSCR Stem Cells & Gene Therapy Symposium

New Immunotherapy Drug for Mesothelioma Gets International Attention at Recent Meeting, According to Surviving Mesothelioma Attendees at a recent international symposium of stem cell researchers learned more about a promising new therapeutic agent for malignant mesothelioma, as the drug moves into the next phase of clinical trials. Raleigh, NC (PRWEB) November 04, 2016 — Scientists with Targovax, the makers of a promising new immunotherapy drug for malignant mesothelioma recently presented their preclinical and clinical data at a meeting hosted by the International Society of Stem Cell Research and the European Society of Gene and Cell Therapy in October.

Read more